Arbutus Biopharma Corp. (NASDAQ:ABUS) fell 2.9% during trading on Friday . The company traded as low as $4.08 and last traded at $4.09, with a volume of 58,453 shares trading hands. The stock had previously closed at $4.21.

Several research firms have issued reports on ABUS. Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Arbutus Biopharma Corp. in a research note on Thursday, May 5th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of Arbutus Biopharma Corp. in a research note on Wednesday, May 4th. Chardan Capital raised shares of Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.25 price target on the stock in a research note on Thursday, June 16th. Finally, Zacks Investment Research raised shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, April 25th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $10.96.

The company’s market cap is $229.42 million. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $3.92.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.20. Equities research analysts anticipate that Arbutus Biopharma Corp. will post ($1.35) earnings per share for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.